Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations

Tools and applications

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease(NAFLD) is the most common cause of chronic liver disease worldwide as a result of the increasing prevalence of obesity, starting from early life stages. It is characterized by a spectrum of liver diseases ranging from simple fatty liver(NAFL) to steatohepatitis(NASH), with a possible progression to fibrosis, thus increasing liver-related morbidity and mortality. NAFLD development is driven by the co-action of several risk factors, including obesity and metabolic syndrome, which may be both genetically induced and diet-related. Recently, particular attention has been paid to the gut-liver axis, which may play a physio-pathological role in the onset and progression of the disease. The gut microbiota is intended to act as a bioreactor that can guarantee autonomous metabolic and immunological functions and that can drive functional strategies within the environment of the body in response to external stimuli. The complexity of the gut microbiota suggests that it behaves as an organ. Therefore, the concept of the gut-liver axis must be complemented with the gut-microbiota-liver network due to the high intricacy of the microbiota components and metabolic activities; these activities form the active diet-driven power plant of the host. Such complexity can only be revealed using systems biology, which can integrate clinical phenomics and gut microbiota data.

Original languageEnglish
Pages (from-to)684-711
Number of pages28
JournalInternational Journal of Molecular Sciences
Volume15
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

liver
Liver
platforms
Fatty Liver
Liver Diseases
Obesity
Diet
Power Plants
obesity
Systems Biology
Microbiota
diets
Bioreactors
Nutrition
Disease Progression
progressions
Fibrosis
Chronic Disease
Morbidity
bioreactors

Keywords

  • Data integration
  • Diet
  • Gut microbiota
  • Meta-omic platforms
  • Metabolic syndrome
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis
  • Obesity
  • Pediatric patients
  • Systems biology

ASJC Scopus subject areas

  • Computer Science Applications
  • Molecular Biology
  • Catalysis
  • Inorganic Chemistry
  • Spectroscopy
  • Organic Chemistry
  • Physical and Theoretical Chemistry
  • Medicine(all)

Cite this

@article{b8faded520514ec6bbf8c044fbbedb44,
title = "Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: Tools and applications",
abstract = "Non-alcoholic fatty liver disease(NAFLD) is the most common cause of chronic liver disease worldwide as a result of the increasing prevalence of obesity, starting from early life stages. It is characterized by a spectrum of liver diseases ranging from simple fatty liver(NAFL) to steatohepatitis(NASH), with a possible progression to fibrosis, thus increasing liver-related morbidity and mortality. NAFLD development is driven by the co-action of several risk factors, including obesity and metabolic syndrome, which may be both genetically induced and diet-related. Recently, particular attention has been paid to the gut-liver axis, which may play a physio-pathological role in the onset and progression of the disease. The gut microbiota is intended to act as a bioreactor that can guarantee autonomous metabolic and immunological functions and that can drive functional strategies within the environment of the body in response to external stimuli. The complexity of the gut microbiota suggests that it behaves as an organ. Therefore, the concept of the gut-liver axis must be complemented with the gut-microbiota-liver network due to the high intricacy of the microbiota components and metabolic activities; these activities form the active diet-driven power plant of the host. Such complexity can only be revealed using systems biology, which can integrate clinical phenomics and gut microbiota data.",
keywords = "Data integration, Diet, Gut microbiota, Meta-omic platforms, Metabolic syndrome, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Obesity, Pediatric patients, Systems biology",
author = "{Del Chierico}, Federica and Daniela Gnani and Pamela Vernocchi and Andrea Petrucca and Anna Alisi and Bruno Dallapiccola and Valerio Nobili and Putignani Lorenza",
year = "2014",
doi = "10.3390/ijms15010684",
language = "English",
volume = "15",
pages = "684--711",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations

T2 - Tools and applications

AU - Del Chierico, Federica

AU - Gnani, Daniela

AU - Vernocchi, Pamela

AU - Petrucca, Andrea

AU - Alisi, Anna

AU - Dallapiccola, Bruno

AU - Nobili, Valerio

AU - Lorenza, Putignani

PY - 2014

Y1 - 2014

N2 - Non-alcoholic fatty liver disease(NAFLD) is the most common cause of chronic liver disease worldwide as a result of the increasing prevalence of obesity, starting from early life stages. It is characterized by a spectrum of liver diseases ranging from simple fatty liver(NAFL) to steatohepatitis(NASH), with a possible progression to fibrosis, thus increasing liver-related morbidity and mortality. NAFLD development is driven by the co-action of several risk factors, including obesity and metabolic syndrome, which may be both genetically induced and diet-related. Recently, particular attention has been paid to the gut-liver axis, which may play a physio-pathological role in the onset and progression of the disease. The gut microbiota is intended to act as a bioreactor that can guarantee autonomous metabolic and immunological functions and that can drive functional strategies within the environment of the body in response to external stimuli. The complexity of the gut microbiota suggests that it behaves as an organ. Therefore, the concept of the gut-liver axis must be complemented with the gut-microbiota-liver network due to the high intricacy of the microbiota components and metabolic activities; these activities form the active diet-driven power plant of the host. Such complexity can only be revealed using systems biology, which can integrate clinical phenomics and gut microbiota data.

AB - Non-alcoholic fatty liver disease(NAFLD) is the most common cause of chronic liver disease worldwide as a result of the increasing prevalence of obesity, starting from early life stages. It is characterized by a spectrum of liver diseases ranging from simple fatty liver(NAFL) to steatohepatitis(NASH), with a possible progression to fibrosis, thus increasing liver-related morbidity and mortality. NAFLD development is driven by the co-action of several risk factors, including obesity and metabolic syndrome, which may be both genetically induced and diet-related. Recently, particular attention has been paid to the gut-liver axis, which may play a physio-pathological role in the onset and progression of the disease. The gut microbiota is intended to act as a bioreactor that can guarantee autonomous metabolic and immunological functions and that can drive functional strategies within the environment of the body in response to external stimuli. The complexity of the gut microbiota suggests that it behaves as an organ. Therefore, the concept of the gut-liver axis must be complemented with the gut-microbiota-liver network due to the high intricacy of the microbiota components and metabolic activities; these activities form the active diet-driven power plant of the host. Such complexity can only be revealed using systems biology, which can integrate clinical phenomics and gut microbiota data.

KW - Data integration

KW - Diet

KW - Gut microbiota

KW - Meta-omic platforms

KW - Metabolic syndrome

KW - Non-alcoholic fatty liver disease

KW - Non-alcoholic steatohepatitis

KW - Obesity

KW - Pediatric patients

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=84891851661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891851661&partnerID=8YFLogxK

U2 - 10.3390/ijms15010684

DO - 10.3390/ijms15010684

M3 - Article

VL - 15

SP - 684

EP - 711

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 1

ER -